SRX251 / Azevan - LARVOL DELTA

Treating mild repetitive head injury with a vasopressin V1a receptor antagonist. (Neuroscience 2022) - "Rats treated with SRX251 presented with a significant decrease in cerebral blood volume along the prefrontal ctx, hippocampus, olfactory system, and midbrain. The drug-induced decrease in blood volume to these areas after repetitive head injury may reflect a period of hypometabolism to help in recovery."

CNS Disorders • Vascular Neurology

Evidence of early vasogenic edema following minor head impact that can be reduced with a vasopressin V1a receptor antagonist. (PubMed, Brain Res Bull) - "A single minor impact to the forehead causes regional increases in vasogenic edema that peak at 6 hrs but return to baseline within a day in a subset of brain regions. Treatment with a selective V1a receptor antagonist can reduce much of the edema."

Journal • Anesthesia • CNS Disorders • Vascular Neurology • MRI

Data on small cardamom transcriptome associated with capsule rot disease. (PubMed, Data Brief) - "The raw data were submitted to NCBI SRA database of under the accession numbers SRX2512359 and SRX2512358 for the control and diseased samples respectively...The data was further used to identify significantly differentially expressed unigenes between control and stressed samples. Assembled unigenes were further annotated and evaluated in silico to predict the function using publicly available databases and gene annotation tools."

Journal